<DOC>
	<DOCNO>NCT00263692</DOCNO>
	<brief_summary>The aim study compare immunogenicity safety GSK Biologicals ' combined DTaP-IPV vaccine separate administration DTaP IPV vaccine , administer fifth dose acellular pertussis vaccine child age 4 6 year co-administered MMR vaccine subject previously receive four dos Infanrix , three dos poliovirus-containing vaccine MMR vaccination .</brief_summary>
	<brief_title>Comparison GSK Biologicals ' DTaP-IPV Candidate Vaccine DTaP IPV Separately Administered Vaccines Terms Immune Response Safety</brief_title>
	<detailed_description />
	<mesh_term>Diphtheria</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Healthy child include 4 6 year age . Previously receive 4 dos GSK Biologicals ' DTaP , 3 dos IPV vaccine 1 dose measles , mumps , rubella vaccine . Use investigational nonregistered drug vaccine study vaccine within 30 day precede administration study vaccine , plan use study period . Chronic administration plan administration immunosuppressant immune modify drug within six month prior study vaccination plan administration study period Administration immunoglobulins and/or blood product within 3 month prior vaccination .</criteria>
	<gender>All</gender>
	<minimum_age>4 Years</minimum_age>
	<maximum_age>6 Years</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>